Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis

Kidney International

Volumn 88, Issue 2, 2015, Pages 378-385

  Lin, Ting Tse ^a   Yang, Yao Hsu ^b,c   Liao, Min Tsun ^a   Tsai, Chia Ti ^c   Hwang, Juey J ^c   Chiang, Fu Tien ^a,c   Chen, Pau Chung ^c   Lin, Jiunn Lee ^c   Lin, Lian Yu ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

ACE inhibitors; chronic kidney disease; hemodialysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; COHORT ANALYSIS; CONTROLLED STUDY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERITONEAL DIALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; TAIWANESE; ADOLESCENT; INCIDENCE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; REGISTER; RENAL REPLACEMENT THERAPY; TAIWAN; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL DIALYSIS; TAIWAN; TIME FACTORS; YOUNG ADULT;

EID: 84938547810     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.96     Document Type: Article

References (52)

1. Heeringa J, Van Der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953
2. Kannel WB, Abbott RD, Savage DD et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-1022
3. Wong CK, White HD, Wilcox RG et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000; 140: 878-885
4. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-2925
5. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844
6. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380
7. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931
8. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557
9. L'Allier PL, Ducharme A, Keller PF et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44: 159-164
10. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719
11. Heckbert SR, Wiggins KL, Glazer NL et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538-544
12. Mathew JP, Fontes ML, Tudor IC et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720-1729
13. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27: 512-518
14. Kushner FG, Hand M, Smith SC Jr. et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205-2241
15. Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479
16. Jassal SV, Coulshed SJ, Douglas JF et al. Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Am J Kidney Dis 1997; 30: 219-223
17. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92
18. Schaer BA, Schneider C, Jick SS et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152: 78-84
19. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 28: 01740-01749
20. Marott SC, Nielsen SF, Benn M et al. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014; 35: 1205-1214
21. Chang CH, Lee YC, Tsai CT et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014; 232: 224-230
22. DiNicolantonio JJ, Beavers CJ, Menezes AR et al. Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2014; 113: 565-569
23. Soliman EZ, Prineas RJ, Go AS et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107
24. Iguchi Y, Kimura K, Kobayashi K et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102: 1056-1059
25. Vazquez E, Sanchez-Perales C, Borrego F et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140: 886-890
26. Fabbian F, Catalano C, Lambertini D et al. Clinical characteristics associated to atrial fibrillation in chronic hemodialysis patients. Clin Nephrol 2000; 54: 234-239
27. Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of long-Term hemodialysis patients. Am J Kidney Dis 2005; 46: 897-902
28. Atar I, Konas D, Acikel S et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006; 106: 47-51
29. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 1098-1106
30. Ansari N, Manis T, Feinfeld DA. Symptomatic atrial arrhythmias in hemodialysis patients. Ren Fail 2001; 23: 71-76
31. Foley RN, Parfrey PS, Kent GM et al. Long-Term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720-1725
32. Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459
33. Obermayr RP, Temml C, Knechtelsdorfer M et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 2008; 23: 1265-1273
34. Wang TJ, Parise H, Levy D et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 2471-2477
35. Watanabe H, Tanabe N, Watanabe T et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008; 117: 1255-1260
36. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174
37. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919
38. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253
39. Fried L, Solomon C, Shlipak M et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15: 3184-3191
40. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891
41. Aviles RJ, Martin DO, Apperson-Hansen C et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010
42. Yeyati NL, Adrogue HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol 1996; 16: 471-477
43. Goette A, Staack T, Rocken C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677
44. K-Laflamme A, Oster L, Cardinal R et al. Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. Hypertension 1997; 30: 278-287
45. Li D, Fareh S, Leung TK et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100: 87-95
46. Clough DP, Collis MG, Conway J et al. Interaction of angiotensinconverting enzyme inhibitors with the function of the sympathetic nervous system. Am J Cardiol 1982; 49: 1410-1414
47. Shi Y, Li D, Tardif JC et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54: 456-461
48. Boldt A, Scholl A, Garbade J et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 2006; 101: 261-267
49. Brookhart MA, Wyss R, Layton JB et al. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013; 6: 604-611
50. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
51. Cepeda MS, Boston R, Farrar JT et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158: 280-287
52. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation 2007; 115: 2340-2343